PRKAR2A and colitis: After challenging with DSS, TSA-treated Prkar2a−/− mice showed exacerbated colitis as compared to non-TSA-treated Prkar2a−/− mice, as assessed by an accelerated weight loss (Fig. 8b), higher histological score (Fig. 8c–d), and severe colon shortening (Fig. 8e).